Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08).
Sunakawa Y, Sakamoto Y, Kawabata R, Ishiguro A, Akamaru Y, Kito Y, Takahashi M, Matsuyama J, Yabusaki H, Makiyama A, Suzuki T, Tsuda M, Yasui H, Hihara J, Takeno A, Inoue E, Ichikawa W, Fujii M. Sunakawa Y, et al. Among authors: matsuyama j. Oncologist. 2024 Aug 5;29(8):e997-e1002. doi: 10.1093/oncolo/oyae056. Oncologist. 2024. PMID: 38581687 Free PMC article.
Clinical outcome and indications for palliative gastrojejunostomy in unresectable advanced gastric cancer: multi-institutional retrospective analysis.
Takeno A, Takiguchi S, Fujita J, Tamura S, Imamura H, Fujitani K, Matsuyama J, Mori M, Doki Y; Clinical Study Group of Osaka University (CSGO), Upper GI Group. Takeno A, et al. Among authors: matsuyama j. Ann Surg Oncol. 2013 Oct;20(11):3527-33. doi: 10.1245/s10434-013-3033-3. Epub 2013 May 29. Ann Surg Oncol. 2013. PMID: 23715966
Effects of an Oral Elemental Nutritional Supplement on Post-gastrectomy Body Weight Loss in Gastric Cancer Patients: A Randomized Controlled Clinical Trial.
Imamura H, Nishikawa K, Kishi K, Inoue K, Matsuyama J, Akamaru Y, Kimura Y, Tamura S, Kawabata R, Kawada J, Fujiwara Y, Kawase T, Fukui J, Takagi M, Takeno A, Shimokawa T. Imamura H, et al. Among authors: matsuyama j. Ann Surg Oncol. 2016 Sep;23(9):2928-35. doi: 10.1245/s10434-016-5221-4. Epub 2016 Apr 15. Ann Surg Oncol. 2016. PMID: 27084538 Clinical Trial.
Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial.
Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, Nagao N, Takahashi M, Takagane A, Watanabe T, Kaji M, Okitsu H, Nomura T, Matsui T, Yoshikawa T, Matsuyama J, Yamada M, Ito S, Takeuchi M, Fujii M. Yoshida K, et al. Among authors: matsuyama j. J Clin Oncol. 2019 May 20;37(15):1296-1304. doi: 10.1200/JCO.18.01138. Epub 2019 Mar 29. J Clin Oncol. 2019. PMID: 30925125 Free PMC article. Clinical Trial.
Long-term effects of an oral elemental nutritional supplement on post-gastrectomy body weight loss in gastric cancer patients (KSES002).
Kimura Y, Nishikawa K, Kishi K, Inoue K, Matsuyama J, Akamaru Y, Tamura S, Kawada J, Kawase T, Kawabata R, Fujiwara Y, Kanno H, Yamada T, Shimokawa T, Imamura H. Kimura Y, et al. Among authors: matsuyama j. Ann Gastroenterol Surg. 2019 Oct 10;3(6):648-656. doi: 10.1002/ags3.12290. eCollection 2019 Nov. Ann Gastroenterol Surg. 2019. PMID: 31788653 Free PMC article.
A Phase II Study of Perioperative Capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601).
Terazawa T, Matsuyama J, Goto M, Kawabata R, Endo S, Imano M, Fujita S, Akamaru Y, Taniguchi H, Tatsumi M, Lee SW, Kurisu Y, Kawakami H, Kurokawa Y, Shimokawa T, Sakai D, Kato T, Fujitani K, Satoh T. Terazawa T, et al. Among authors: matsuyama j. Oncologist. 2020 Feb;25(2):119-e208. doi: 10.1634/theoncologist.2019-0601. Epub 2019 Sep 30. Oncologist. 2020. PMID: 32043772 Free PMC article. Clinical Trial.
Comparison of S-1-cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials.
Kawakami H, Fujitani K, Matsuyama J, Akamaru Y, Tamura S, Endo S, Kimura Y, Makari Y, Tamura T, Sugimoto N, Sakai D, Tsujinaka T, Goto M, Kurokawa Y, Shimokawa T, Satoh T; Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG). Kawakami H, et al. Among authors: matsuyama j. Int J Clin Oncol. 2020 Sep;25(9):1635-1643. doi: 10.1007/s10147-020-01711-z. Epub 2020 Jun 3. Int J Clin Oncol. 2020. PMID: 32494981 Clinical Trial.
193 results